Eisai Launches BELVIQ® Patient Support Program Offering On-Line Tools to Enhance Weight Loss Efforts

   Eisai Launches BELVIQ® Patient Support Program Offering On-Line Tools to
                         Enhance Weight Loss Efforts

The BELIEVE EVERYDAY SUPPORTSM Program Offers Customized Lifestyle Resources
and Free Membership to Top Calorie Tracking App for Use by BELVIQ® (lorcaserin
HCl) CIV Patients

PR Newswire

WOODCLIFF LAKE, N.J., Sept. 12, 2013

WOODCLIFF LAKE, N.J., Sept. 12, 2013 /PRNewswire/ -- Eisai Inc. today
announced the availability of the BELIEVE EVERYDAY SUPPORT^SM program to
provide free, comprehensive support and savings for BELVIQ^® (lorcaserin HCl)
CIV patients, including a customizable online portal designed to help some
patients reach their weight loss goals and sustain their efforts.

(Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO )

"The BELIEVE EVERYDAY SUPPORT program is an extension of Eisai's human health
care commitment to put patients and their families first. By providing BELVIQ
patients with a truly useful, informative and educational platform, we are
helping patients take the right steps towards losing weight and keeping that
weight off," said Michael O'Brien, Vice President, Specialty Marketing and
Sales Business Unit for Eisai. "Through a BELVIQ savings card, diet and
exercise tips, calorie and activity tracking and offering nutritious recipes
that meet patients' specific dietary needs, the program is designed to support
efforts with BELVIQ treatment to help patients lead a healthy lifestyle in a
way that works for them."

Patients who obtain a BELVIQ prescription can enroll for free online at
BelieveSupport.com. The support program includes:

  oA monthly savings card for commercially insured or cash-paying patients
    (restrictions apply)
  oOne-year full membership to Lose It!, the #1 downloaded app for tracking
    calories and activity
  oNutrition information and helpful advice from the experts at EatingWell^®
  oTools for meal planning
  oTips to help patients stay motivated and reminders to help stay on track

Patients will have access to hundreds of EatingWell healthy recipes to help
plan reduced calorie meals as part of BELVIQ therapy and the ability to search
for them by specific ingredient or dietary need, as well as a 28-day meal
planning tool vetted by EatingWell test kitchen experts. "Eating healthy
requires meal planning and an understanding of your individual nutritional
needs," said Renee Lauber, director of Health and Wellness Business
Development at EatingWell. "This program makes it easy for patients to plan
ahead and make healthy choices that may help encourage them on their path for
successful weight loss and maintenance."

Physical activity is also an important component of BELVIQ treatment, but with
the sudden influx of mobile apps and online tools available to help people
lose weight, it can be hard to navigate which one will be effective. "Patients
need a tool that allows them to customize their own weight loss program that
fits into their lifestyle in order to achieve their desired results," said
Kevin McCoy, senior vice president of Business Development at Lose It!. "Lose
It! is based on the proven principles of calorie tracking and peer support for
healthy, sustainable weight loss. We seamlessly connect you to the tools and
food information needed during your weight loss journey as part of the BELIEVE
EVERYDAY SUPPORT program."

About BELVIQ^® (lorcaserin HCl) CIV Tablets
BELVIQ is used along with a reduced-calorie diet and increased physical
activity for chronic weight management in adults who have a body mass index
(BMI) of 30 kg/m^2 or greater (obese), or

BMI of 27 kg/m^2 or greater (overweight) with at least one weight-related
medical condition such as high blood pressure, high cholesterol, or type 2
diabetes. It is not known if BELVIQ is safe and effective when taken with
other prescription, over-the-counter, or herbal weight loss products, nor is
it known if BELVIQ changes the risk of heart problems or stroke, or of death
due to heart problems or stroke.

BELVIQ is believed to decrease food consumption and promote satiety by
selectively activating serotonin 2C receptors in the brain. The exact
mechanism of action of BELVIQ is not known.

For more information about BELVIQ, click here for the full Product Information
or visit www.BELVIQ.com.

Important Safety Information

  oPregnancy: Do not take BELVIQ if you are pregnant or planning to become
    pregnant, as weight loss offers no potential benefit during pregnancy
    and BELVIQ may harm your unborn baby.
  oSerotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like reactions:
    Before using BELVIQ, tell your doctor about all the medicines you take,
    especially medicines that treat depression, migraines, mental problems, or
    the common cold. These medicines may cause serious or life-threatening
    side effects if taken with BELVIQ. Call your doctor right away if you
    experience agitation, hallucinations, confusion, or other changes in
    mental status; coordination problems; uncontrolled muscle spasms; muscle
    twitching; restlessness; racing or fast heartbeat; high or low blood
    pressure; sweating; fever; nausea; vomiting; diarrhea; or stiff muscles.
  oValvular heart disease: Some people taking medicines like BELVIQ have had
    heart valve problems. Call your doctor right away if you experience
    trouble breathing; swelling of the arms, legs, ankles, or feet; dizziness,
    fatigue, or weakness that will not go away; or fast or irregular
    heartbeat. Before taking BELVIQ, tell your doctor if you have or have had
    heart problems.
  oChanges in attention or memory: BELVIQ may slow your thinking. You should
    not drive a car or operate heavy equipment until you know how BELVIQ
    affects you.
  oMental problems: Taking too much BELVIQ may cause hallucinations, a
    feeling of being high or in a very good mood, or feelings of standing
    outside your body.
  oDepression or thoughts of suicide: Call your doctor right away if you
    notice any mental changes, especially sudden changes in your mood,
    behaviors, thoughts, or feelings, or if you have depression or thoughts of
    suicide.
  oLow blood sugar: Weight loss can cause low blood sugar in people taking
    medicines for type 2 diabetes, such as insulin or sulfonylureas. Blood
    sugar levels should be checked before and while taking BELVIQ. Changes to
    diabetes medication may be needed if low blood sugar develops.
  oPainful erections: If you have an erection lasting more than 4 hours while
    on BELVIQ, stop taking BELVIQ and call your doctor or go to the nearest
    emergency room right away.
  oSlow heartbeat: BELVIQ may cause your heart to beat slower.
  oDecreases in blood cell count: BELVIQ may cause your red and white blood
    cell counts to decrease.
  oIncrease in prolactin: BELVIQ may increase the amount of a hormone called
    prolactin. Tell your doctor if your breasts begin to make milk or a milky
    fluid, or if you are a male and your breasts increase in size.
  oMost common side effects in patients without diabetes: Headache,
    dizziness, fatigue, nausea, dry mouth, and constipation.
  oMost common side effects in patients with diabetes: Low blood sugar,
    headache, back pain, cough, and fatigue.
  oNursing: BELVIQ should not be taken while breastfeeding.
  oDrug interactions: Before taking BELVIQ, tell your doctor if you take
    medicines for depression, migraines, or other medical conditions, such as:
    triptans; medicines used to treat mood, anxiety, psychotic or thought
    disorders, including tricyclics, lithium, selective serotonin reuptake
    inhibitors, selective serotonin-norepinephrine reuptake inhibitors,
    monoamine oxidase inhibitors, or antipsychotics; cabergoline; linezolid
    (an antibiotic); tramadol; dextromethorphan (an over-the-counter (OTC)
    common cold/cough medicine); OTC supplements such as tryptophan or St.
    John's Wort; or erectile dysfunction medicines.

BELVIQ is a federally controlled substance (CIV) because it may be abused or
lead to drug dependence.

For more information about BELVIQ, click here for the full Product Information
or visit www.BELVIQ.com.

About Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to
patients and their families, and helping to increase the benefits health care
provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co.,
Ltd., our passionate commitment to patient care is the driving force behind
our efforts to help address unmet medical needs. We are a fully integrated
pharmaceutical business with discovery, clinical, manufacturing and marketing
capabilities. Our key areas of commercial focus include oncology and specialty
care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more
about Eisai Inc., please visit us at www.eisai.com/US.

Eisai Inc. has affiliates that are part of a global product creation
organization that includes R&D facilities in Massachusetts, New Jersey, North
Carolina and Pennsylvania, as well as a global demand chain organization that
includes manufacturing facilities in Maryland and North Carolina. Eisai's
global areas of R&D focus include neuroscience; oncology; metabolic disorders;
vascular, inflammatory and immunological reaction; and antibody-based
programs.



Media Inquiries    Investor Inquiries
Marcia Diljak      Alex Scott
Eisai Inc.          Eisai Inc.
(201) 746-2236     (201) 746-2177

SOURCE Eisai Inc.

Website: http://www.eisai.com
 
Press spacebar to pause and continue. Press esc to stop.